Key Points Question How often has the 2020 Predictive Approaches to Treatment Heterogeneity (PATH) Statement been cited in published predictive models …
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Bruce Fireman
Impact of the PATH Statement on Analysis and Reporting of Heterogeneity of Treatment Effect in Clinical Trials: A Scoping Review
The authors have declared no competing interest. Drs. Selby and Maas and Mr. Fireman report no funding related to work performed on this publication. Dr. Kent was funded by a National Institutes of Health (NIH)/National Center for Advancing Translational Sciences (NCATS) grant (UM1TR004398-01). Dr. Selby previously served as the Executive Director of the Patient-Centered Outcomes Research Institute (PCORI).
Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting
Authors: Ousseny Zerbo, PhD; Joan Bartlett, MPH; Bruce Fireman; Ned Lewis, MPH; Kristin Goddard, MPH; Kathleen Dooling, MD; Jonathan Duffy, MD; Jason Glanz, PhD; Allison Naleway, PhD; James G. Donahue, DVM, PhD, MPH; Nicola P.
Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age
December 14, 2023 N Engl J Med 2023; 389:2245-2255 DOI: 10.1056/NEJMoa2302099 Abstract Quadrivalent recombinant influenza vaccines contain three times the amount of hemagglutinin protein as standard-dose egg-based vaccines, and the recombinant formulation is not susceptible to antigenic drift during manufacturing. Data are needed on the relative effectiveness of recombinant vaccines as compared with standard-dose vaccines against influenza-related outcomes in adults under the age of 65 years.
Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records
We calculated the incidence of HZ, postherpetic neuralgia, HZO, and admission to hospital for HZ by vaccination status overall and by age group (50-59, 60-69, 70-79, and ≥80 years). We also calculated the percentage of HZ cases who had postherpetic neuralgia, HZO, or admission to hospital for HZ. For each outcome, we examined the vaccine effectiveness of live zoster vaccine using Cox regression.
Bivalent mRNA Vaccine Durability in Preventing Severe Disease
|
By Ruth Link-Gelles, Zachary Weber, Sarah Reese, Amanda Payne, Manjusha Gaglani, Katherine Adams, Anupam B. Kharbanda, Karthik Natarajan, Malini DeSilva, Kristin Dascomb, Stephanie A. Irving, Nicola P. Klein, Shaun Grannis, Toan C Ong, Peter J Embi, Margaret Dunne, Monica Dickerson, Charlene E. McEvoy, Julie Arndorfer, Allison L. Naleway, Kristin Goddard, Brian Dixon, Eric Griggs, John Hansen, Nimish R Valvi, Morgan Najdowski, Julius Timbol, Colin Rogerson, Bruce Fireman, William F Fadel, Palak Patel, Caitlin Ray, Ryan Wiegand, Sarah Ball, Mark W. Tenforde
|
Medscape
Verified
Abstract and Introduction Introduction On September 1, 2022, CDC's Advisory Committee on Immunization Practices (ACIP) recommended a single bivalent mRNA COVID-19 booster dose for persons aged ≥12 years who had completed at least a monovalent primary series.
Antibiotic prescribing across age groups in the Kaiser Permanente Northern California population in association with different diagnoses, and with influenza incidence, 2010–2018 | Epidemiology & Infection | Cambridge Core
Hostname: page-component-5f5657f67b-lxwhp Total loading time: 0.793 Render date: 2022-05-04T06:40:51.584Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true } Published online by Cambridge University Press: 24 February 2022 Edward Goldstein [Opens in a new window] , Marc Lipsitch [Opens in a new window] and Show author details Rights & Permissions[Opens in a new window]...
Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink
Figure. Timing of GBS Symptom Onset after COVID-19 Vaccination (opens in new tab) A, Bars represent the number of confirmed cases of GBS after Ad.26.COV2.S vaccination (N = 11). The x-axis denotes the numbers of days between Ad.26.COV2.S vaccination and GBS symptom onset. The 84-day follow-up period has elapsed for all Ad.26.COV2.S vaccinations.
Guillain-Barré Syndrome after COVID-19 Vaccination in the Vaccine Safety Datalink
Kayla E. Hanson, Kristin Goddard, Ned Lewis, Bruce Fireman, Tanya R. Myers, Nandini Bakshi, Eric Weintraub, James G. Donahue, Jennifer C. Nelson, Stan Xu, Jason M. Glanz, Joshua T.B. Williams, Jonathan D. Alpern, Nicola P. Klein doi: https://doi.org/10.1101/2021.12.03.21266419 Abstract Importance Post-authorization monitoring of vaccines in a large population can detect rare adverse events not identified in clinical trials including Guillain-Barré syndrome (GBS).
Surveillance for Adverse Events After COVID-19 mRNA Vaccination
Key Points Question Are mRNA COVID-19 vaccines associated with increased risk for serious health outcomes during days 1 to 21 after vaccination? Findings In this interim analysis of surveillance data from 6.2 million persons who received 11.8 million doses of an mRNA vaccine, event rates for 23 serious health outcomes were not significantly higher for individuals 1 to 21 days after vaccination compared with similar individuals at 22 to 42 days after vaccination.
Acellular Pertussis Vaccine Effectiveness Over Time
Abstract OBJECTIVES: To determine pertussis risk by diphtheria-tetanus-acellular pertussis (DTaP) vaccination status and time since last DTaP dose.
Comparative Effectiveness of Acellular Versus Whole-Cell Pertussis Vaccines in Teenagers
Abstract BACKGROUND: During the 1990s, the United States switched from combined diphtheria, tetanus toxoids, whole-cell pertussis (DTwP) vaccines to combined acellular pertussis (DTaP) vaccines because of safety concerns. After a 2010–2011 pertussis outbreak, we sought to evaluate whether disease risk in 10 to 17 year olds differed between those who previously received DTwP from those who received DTaP.
Effectiveness of Vaccination During Pregnancy to Prevent Infant Pertussis
Abstract BACKGROUND: Vaccination against pertussis during pregnancy is recommended to protect newborns, yet there is limited information about the effectiveness of maternal tetanus toxoid, reduced diphtheria toxoid, acellular pertussis (Tdap) vaccine before the first infant dose of diphtheria, tetanus and acellular pertussis (DTaP) vaccine and during the first year of life in infants who have received DTaP.
Effectiveness of Vaccination During Pregnancy to Prevent Infant Pertussis
Effectiveness of Vaccination During Pregnancy to Prevent Infant Pertussis Roger Baxter, Joan Bartlett, Bruce Fireman, Edwin Lewis, Nicola P. Klein Pediatrics Apr 2017, e20164091; DOI: 10.1542/peds.2016-4091
Association Between Influenza Infection and Vaccination During Pregnancy and Risk of Autism Spectrum Disorder
Key Points Question Is there an association between maternal influenza infection and vaccination and autism risk? Findings In a cohort study of 196 929 children, of whom 3103 had austism spectrum disorder, maternal influenza infection during pregnancy was not associated with increased autism risk.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Bruce
Contact Bruce, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack